Selecta Biosciences, Inc. (NASDAQ: SELB), a biotechnology company leveraging its clinically validated ImmTOR™ platform to develop tolerogenic therapies that selectively mitigate unwanted immune responses, today announced that that it plans to host a conference call on Thursday, May 13, 2021, at 8:30 a.m. ET to discuss its financial results for the quarter ended March 31, 2021